Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan Buys 261,752 Shares

Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan acquired 261,752 shares of Ventyx Biosciences stock in a transaction dated Monday, November 25th. The shares were acquired at an average price of $2.01 per share, with a total value of $526,121.52. Following the completion of the transaction, the chief executive officer now owns 2,175,028 shares of the company’s stock, valued at approximately $4,371,806.28. This trade represents a 13.68 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Raju Mohan also recently made the following trade(s):

• On Friday, November 22nd, Raju Mohan bought 238,248 shares of Ventyx Biosciences stock. The shares were acquired at an average cost of $1.83 per share, for a total transaction of $435,993.84.

Ventyx Biosciences Trading Up 11.4 %

NASDAQ:VTYX traded up $0.21 during mid-day trading on Monday, reaching $2.06. 2,159,733 shares of the stock were exchanged, compared to its average volume of 2,033,156. The business has a fifty day moving average price of $2.19 and a 200 day moving average price of $2.64. Ventyx Biosciences, Inc. has a 1-year low of $1.67 and a 1-year high of $11.48. The firm has a market capitalization of $145.66 million, a PE ratio of -0.86 and a beta of 0.37.

Hedge Funds Weigh In On Ventyx Biosciences

Several hedge funds have recently made changes to their positions in VTYX. Ikarian Capital LLC boosted its holdings in Ventyx Biosciences by 8,483.8% during the first quarter. Ikarian Capital LLC now owns 507,647 shares of the company’s stock worth $2,792,000 after buying an additional 501,733 shares in the last quarter. Farallon Capital Management LLC bought a new stake in shares of Ventyx Biosciences during the 1st quarter worth $17,435,000. Opaleye Management Inc. grew its holdings in shares of Ventyx Biosciences by 12.7% in the 1st quarter. Opaleye Management Inc. now owns 1,285,000 shares of the company’s stock worth $7,068,000 after acquiring an additional 145,000 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Ventyx Biosciences during the second quarter worth $32,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Ventyx Biosciences by 58.4% during the second quarter. Bank of New York Mellon Corp now owns 230,593 shares of the company’s stock valued at $533,000 after purchasing an additional 84,984 shares during the last quarter. Institutional investors and hedge funds own 97.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on VTYX shares. Wells Fargo & Company lowered their price target on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. HC Wainwright reissued a “neutral” rating and set a $6.00 target price on shares of Ventyx Biosciences in a research note on Monday, November 11th. Canaccord Genuity Group dropped their price target on shares of Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $9.00 price objective (down from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Ventyx Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.